Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides

被引:61
作者
Patel, HJ
Ramkissoon, SH
Patel, PS
Rameshwar, P [1 ]
机构
[1] Univ Med & Dent New Jersey, Dept Med, Newark, NJ 07103 USA
[2] Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07103 USA
[3] Brookdale Univ Hosp, Dept Surg, Brooklyn, NY 11212 USA
[4] Med Ctr, Brooklyn, NY 11212 USA
关键词
breast cancer; cytokines; bone marrow metastasis; substance P; tachykinin;
D O I
10.1073/pnas.0506351102
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Breast cancer remains the cancer with the highest mortality among women in the United States. Peptides derived from the oncogenic Tac1 gene (full transcript: beta PPT-A) stimulate the proliferation of breast cancer cells (BCCs) via seven-transmembrane G protein-coupled neurokinin 1 (NK1) and NK2 receptors. The NK1 gene could generate full-length (NK1-FL) and truncated (NK1-Tr) transcripts. NK1-Tr lacks 100 residues in their cytoplasmic end, could couple to G proteins, and shows reduced efficiency with respect to internalization and desensitization. This study reports on a role of NK1-Tr in the transformation of nonturnorigenic breast cells, and investigates whether Tac1 expression is linked to the generation of NK1-Tr. Western blots and Northern analyses showed coexpressions of NK1-Tr and NK1-FL in BCCs (cell lines and primary cells from patients with different stages of breast cancer). Stable transfections of beta PPT-A or NK1-Tr expression vectors in nonturnorigenic cells showed each induces the expression of the other, consequently resulting in a transformed phenotype. Analyses with microarrays indicate similar patterns of cytokine production by NK1-Tr transfectants and BCCs, but not NK1-FL transfectants. These observations indicate tumor-promoting properties by NK1-Tr, but not NK1-FL. Overall, the oncogenic property of Tac1 in breast cells involves concomitant expression of NK1-Tr and vice versa, consequently leading to the production of cytokines with growth promoting functions.
引用
收藏
页码:17436 / 17441
页数:6
相关论文
共 29 条
[1]   Truncated, desensitization-defective neurokinin receptors mediate sustained MAP kinase activation, cell growth and transformation by a Ras-independent mechanism [J].
Alblas, J ;
vanEtten, I ;
Moolenaar, WH .
EMBO JOURNAL, 1996, 15 (13) :3351-3360
[2]   Crosstalk between neurokinin receptors is relevant to hematopoietic regulation: cloning and characterization of neurokinin-2 promoter [J].
Bandari, PS ;
Qian, J ;
Oh, HS ;
Potian, JA ;
Yehia, G ;
Harrison, JS ;
Rameshwar, P .
JOURNAL OF NEUROIMMUNOLOGY, 2003, 138 (1-2) :65-75
[3]   A 25 year adventure in the field of tachykinins [J].
Beaujouan, JC ;
Torrens, Y ;
Saffroy, M ;
Kernel, ML ;
Glowinski, J .
PEPTIDES, 2004, 25 (03) :339-357
[4]   Protein kinase C-mediated desensitization of the neurokinin 1 receptor [J].
Déry, O ;
Defea, KA ;
Bunnett, NW .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2001, 280 (05) :C1097-C1106
[5]   Specific inhibition of glucocorticoid-induced thymocyte apoptosis by substance P [J].
Dimri, R ;
Sharabi, Y ;
Shoham, J .
JOURNAL OF IMMUNOLOGY, 2000, 164 (05) :2479-2486
[6]   STIMULATION OF ANGIOGENESIS BY SUBSTANCE-P AND INTERLEUKIN-1 IN THE RAT AND ITS INHIBITION BY NK1 OR INTERLEUKIN-1 RECEPTOR ANTAGONISTS [J].
FAN, TPD ;
HU, DE ;
GUARD, S ;
GRESHAM, GA ;
WATLING, KJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (01) :43-49
[7]  
FONG TM, 1992, MOL PHARMACOL, V41, P24
[8]   Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer [J].
Friess, H ;
Zhu, ZW ;
Liard, V ;
Shi, X ;
Shrikhande, SV ;
Wang, L ;
Lieb, K ;
Korc, M ;
Palma, C ;
Zimmermann, A ;
Reubi, JC ;
Büchler, MW .
LABORATORY INVESTIGATION, 2003, 83 (05) :731-742
[9]   Tachykinins in the emerging immune system: Relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells [J].
Greco, SJ ;
Corcoran, KE ;
Cho, KJ ;
Rameshwar, P .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 :1782-1793
[10]   TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors [J].
Grotzer, MA ;
Janss, AJ ;
Fung, KM ;
Biegel, JA ;
Sutton, LN ;
Rorke, LB ;
Zhao, H ;
Cnaan, A ;
Phillips, PC ;
Lee, VMY ;
Trojanowski, JQ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) :1027-1035